Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib
Authors:
- Yu-Ning ShihYSYu-Ning Shih
- Chun-Ming TsaiCTChun-Ming Tsai
- Jia-Ling LiouJLJia-Ling Liou
- Yuh-Min ChenYCYuh-Min Chen
- Reury-Perng PerngRPReury-Perng Perng
- 1 August 2007
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 57 (2) , 213-221
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicityLung Cancer, 2005
- Docetaxel Versus Docetaxel Plus Cisplatin As Front-Line Treatment of Patients With Advanced Non—Small-Cell Lung Cancer: A Randomized, Multicenter Phase III TrialJournal of Clinical Oncology, 2004
- Biomarkers, Surrogate End Points, and the Acceleration of Drug Development for Cancer Prevention and TreatmentClinical Cancer Research, 2004
- Interobserver and Intraobserver Variability in Measurement of Non–Small-Cell Carcinoma Lung Lesions: Implications for Assessment of Tumor ResponseJournal of Clinical Oncology, 2003
- Definitions of biochemical failure in prostate cancer following radiation therapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001
- Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancerInternational Journal of Colorectal Disease, 2001
- Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II TrialsJournal of Clinical Oncology, 2000
- Comparison of Standard and CA-125 Response Criteria in Patients With Epithelial Ovarian Cancer Treated With Platinum or PaclitaxelJournal of Clinical Oncology, 1999
- Decline of posttreatment tumor marker levels after therapy of nonsmall cell lung cancer. A useful outcome predictorCancer, 1995
- The value of serial carcinoembryonic antigen (CEA) in predicting response rate and survival of patients with gastrointestinal cancer treated with chemotherapy. A Southwest oncology group studyCancer, 1979